Letter to OMB Director Mick Mulvaney Regarding PBM Safe Harbor Rule


Excerpt: “While the details of the proposed rule are unavailable during the period of review, the publicly available title of the rule indicates that the action contemplated could be significant in scope, with the potential to dramatically change the process by which prescription drugs are purchased within the supply chain. Depending on the nature of the policies contemplated, possible changes could ripple across the health care sector, altering a major sector of the U.S. economy that Americans depend upon for their health and well-being. As such, we ask that you ensure that the proposed rule include a robust regulatory impact analysis prior to clearing it for publication.”

To read a copy of the letter, click here.

Health (115th Congress)